{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:13:50Z","timestamp":1791249230806,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cld.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:37:38Z","timestamp":1740400658000},"page":"287-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunosuppression Post-Liver Transplant"],"prefix":"10.1016","volume":"29","author":[{"given":"Maria L.","family":"Yataco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Keaveny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2024.12.006_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrgastro.2013.88","article-title":"Liver transplantation: past, present and future","volume":"10","author":"Zarrinpar","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2024.12.006_bib2","author":"Kwong"},{"key":"10.1016\/j.cld.2024.12.006_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2024.12.006_bib4","first-page":"659","article-title":"Homotransplantation of the liver in humans","volume":"117","author":"Starzl","year":"1963","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.cld.2024.12.006_bib5","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMp048256","article-title":"Transplantation--a medical miracle of the 20th century","volume":"351","author":"Morris","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/hep.1840020516","article-title":"Evolution of liver transplantation","volume":"2","author":"Starzl","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000658-196809000-00009","article-title":"Orthotopic homotransplantation of the human liver","volume":"168","author":"Starzl","year":"1968","journal-title":"Ann Surg"},{"key":"10.1016\/j.cld.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cld.2024.12.006_bib9","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"10.1016\/j.cld.2024.12.006_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJM198107303050507","article-title":"Liver transplantation with use of cyclosporin a and prednisone","volume":"305","author":"Starzl","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2024.12.006_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/TP.0000000000003350","article-title":"Thirty years of tacrolimus in clinical practice","volume":"105","author":"Ong","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","article-title":"FK 506 for liver, kidney, and pancreas transplantation","volume":"2","author":"Starzl","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2024.12.006_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00000658-199409000-00006","article-title":"Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression","volume":"220","author":"Todo","year":"1994","journal-title":"Ann Surg"},{"key":"10.1016\/j.cld.2024.12.006_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2024.12.006_bib16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A\u00a0comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2024.12.006_bib17","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cld.2024.12.006_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.12659\/AOT.889299","article-title":"Mycophenolate mofetil in liver transplantation: a review","volume":"18","author":"Kaltenborn","year":"2013","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib20","first-page":"43","article-title":"Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial","volume":"5","author":"Sterneck","year":"2000","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1600-6143.2011.03486.x","article-title":"Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study","volume":"11","author":"Boudjema","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.transproceed.2010.08.066","article-title":"Patterns of injury in mycophenolate mofetil-related colitis","volume":"42","author":"Al-Absi","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cld.2024.12.006_bib23","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","article-title":"Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes","volume":"32","author":"Parfitt","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cld.2024.12.006_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2020.07.040","article-title":"Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients","volume":"74","author":"Colmenero","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.12.006_bib25","doi-asserted-by":"crossref","first-page":"193S","DOI":"10.1016\/S0041-1345(03)00234-3","article-title":"Sirolimus in liver transplantation","volume":"35","author":"Trotter","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cld.2024.12.006_bib26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-199902270-00002","article-title":"Sirolimus: a potent new immunosuppressant for liver transplantation","volume":"67","author":"Watson","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib27","first-page":"464","article-title":"Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients","volume":"2","author":"Wiesner","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib28","article-title":"The safety and efficacy of sirolimus and low-dose tacrolimus vs. tacrolimus in de novo orthotopic liver transplant recipients: results from a pilot study","volume":"36","author":"Wiesner","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib29","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A\u00a0randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation","volume":"14","author":"Sterneck","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib31","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/lt.26298","article-title":"Early everolimus-Facilitated reduced tacrolimus in liver transplantation: results from the randomized HEPHAISTOS trial","volume":"28","author":"Nashan","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib32","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1600-6143.2011.03919.x","article-title":"Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial","volume":"12","author":"Abdelmalek","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation Society Consensus Statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/TP.0000000000001438","article-title":"Use of everolimus in liver transplantation: Recommendations from a working group","volume":"101","author":"De Simone","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/tri.12100","article-title":"Induction immunosuppression in liver transplantation: a review","volume":"26","author":"Turner","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.cld.2024.12.006_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007890-199301000-00017","article-title":"OKT3 rescue for steroid-resistant rejection in adult liver transplantation","volume":"55","author":"Solomon","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOT.0b013e32832b45d0","article-title":"Alemtuzumab and liver transplantation: a review","volume":"14","author":"Dhesi","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): a systematic review in organ transplantation","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib40","first-page":"1601","article-title":"Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects","volume":"32","author":"Bamoulid","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.24385","article-title":"Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies","volume":"54","author":"Goralczyk","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib42","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.13182","article-title":"Renal function in de novo liver transplant recipients receiving different Prolonged-release tacrolimus regimens-the DIAMOND study","volume":"15","author":"TruneCka","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib43","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.transproceed.2006.10.110","article-title":"Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24\u00a0months","volume":"38","author":"Ramirez","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cld.2024.12.006_bib44","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trre.2018.04.001","article-title":"Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression","volume":"32","author":"Cillo","year":"2018","journal-title":"Transplant Rev"},{"key":"10.1016\/j.cld.2024.12.006_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/LVT.0000000000000244","article-title":"Long-term outcomes (beyond 5 years) of liver transplant recipients-A transatlantic multicenter study","volume":"30","author":"Palaniyappan","year":"2024","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib47","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1111\/ajt.16585","article-title":"Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: a scoping review","volume":"21","author":"Appenzeller-Herzog","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hep.26576","article-title":"Immunosuppression withdrawal following liver transplantation: the older, the wiser\u2026 but maybe too late","volume":"58","author":"Levitsky","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib49","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.12.006_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100760","article-title":"Immunotolerance in liver transplantation: a primer for the clinician","volume":"28","author":"Perez-Escobar","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cld.2024.12.006_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S2468-1253(16)30208-4","article-title":"Can immunosuppression be stopped after liver transplantation?","volume":"2","author":"Clavien","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2024.12.006_bib52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/lt.22265","article-title":"Operational tolerance: past lessons and future prospects","volume":"17","author":"Levitsky","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008793","article-title":"HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans","volume":"6","author":"Bohne","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cld.2024.12.006_bib54","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/hep.31520","article-title":"Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: Moving toward Personalized management","volume":"73","author":"Feng","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.31036","article-title":"Immunosuppression withdrawal in liver transplant recipients on sirolimus","volume":"72","author":"Levitsky","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib56","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/ajt.15205","article-title":"Outcomes of immunosuppression minimization and withdrawal early after liver transplantation","volume":"19","author":"Shaked","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib57","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A\u00a0pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib58","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.26474","article-title":"Operational tolerance is not always permanent: a 10-year prospective study in pediatric liver transplantation recipients","volume":"28","author":"Wozniak","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib59","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/lt.25963","article-title":"Improvements in disease-specific health-related Quality of life of pediatric liver transplant recipients during immunosuppression withdrawal","volume":"27","author":"Mohammad","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trim.2008.08.007","article-title":"The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78\u00a0months","volume":"20","author":"Orlando","year":"2008","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.cld.2024.12.006_bib61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1399-0012.2008.00944.x","article-title":"Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients","volume":"23","author":"Pons","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib62","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep.26426","article-title":"Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients","volume":"58","author":"Benitez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib63","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"Comprehensive update of the Banff working group on liver allograft Pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2024.12.006_bib64","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2018.08.023","article-title":"Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants","volume":"155","author":"Feng","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2024.12.006_bib65","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jhep.2021.08.007","article-title":"Non-invasive alloimmune risk stratification of long-term liver transplant recipients","volume":"75","author":"Vionnet","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.12.006_bib66","article-title":"Nucleic acid biomarkers to assess graft injury after liver transplantation","volume":"4","author":"Bardhi","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2024.12.006_bib67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hep.28786","article-title":"An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection","volume":"65","author":"Shaked","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.12.006_bib68","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/lt.25842","article-title":"MicroRNAs 155-5p, 122-5p, and 181a-5p identify patients with graft dysfunction due to T\u00a0cell-mediated rejection after liver transplantation","volume":"26","author":"Ruiz","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib69","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/TP.0000000000003815","article-title":"Serum MicroRNA Transcriptomics and acute rejection or recurrent hepatitis C Virus in human liver allograft recipients: a pilot study","volume":"106","author":"Muthukumar","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2024.12.006_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002286","article-title":"Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study","volume":"14","author":"Schutz","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.cld.2024.12.006_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/lt.26272","article-title":"Monitoring of donor-derived cell-free DNA by short tandem repeats: concentration of total cell-free DNA and fragment size for acute rejection risk assessment in liver transplantation","volume":"28","author":"Fernandez-Galan","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2024.12.006_bib72","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1172\/JCI59411","article-title":"Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation","volume":"122","author":"Bohne","year":"2012","journal-title":"J\u00a0Clin Invest"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T23:24:47Z","timestamp":1750375487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326124001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1089326124001132"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2024.12.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression Post-Liver Transplant","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}